SK bioscience, which won the patent infringement lawsuit against Pfizer, is showing strength in early trading on the 21st.
As of 9:24 a.m. on this day, SK bioscience is trading at 43,750 won, up 3,100 won (7.63%) compared to the previous trading day. At one point during the day, the increase rate rose to 10%, reaching 45,100 won.
SK bioscience noted that it received a final ruling from the Supreme Court regarding the patent infringement lawsuit related to the 13-valent pneumococcal concentrate.
SK bioscience developed the 13-valent pneumococcal vaccine 'Sky Pneumo Prefilled Syringe,' but Pfizer filed a patent infringement lawsuit. Following the court's mediation recommendation, it is currently not producing or selling domestically.
However, when SK bioscience instead exported research pneumococcal concentrate to Russia, Pfizer claimed it violated the settlement decision and filed a lawsuit.